← All trials
NCT03598270
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2018
- Primary completion
- May 31, 2023
- Completion date
- Nov 30, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 414
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Grupo Español de Investigación en Cáncer de OvarioLead sponsor
- RocheCollaborator
- Apices Soluciones S.L.Collaborator
- Clinica Universidad de NavarraOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.